Abstract
China’s advances in the field together with the size of its scientific community and resources, position it at the forefront of biotechnological and gene editing research. Most recently, the still unconfirmed report of the first life birth of humans following IVF and gene editing techniques, has place China at the center of the global scientific, socio-ethical, and legal debates. This makes understanding the Chinese regulatory framework and the strength of its governance to address the vast scientific, social, ethical, and political global implications of germline genome modification paramount. This chapter explores how the legal system in the People’s Republic of China (PRC) regulates human gene editing with particular focus on germline applications. It further outlines existing governance frameworks and addresses the possibility of policy convergence by contrasting Chinese approaches to those adopted worldwide.